On May 5, 2021, ICER released its Draft Evidence Report entitled, “Aducanumab for Alzheimer’s Disease.”  Patients Rising Now submitted comments on the draft report.  As stated in the comments, the goal for researchers and clinicians – and hope for patients – is to have effective, safe, and easy-to-administer treatments for Alzheimer’s disease. But that goal will be achieved through incremental progress, and we are very concerned that ICER’s draft report will impair or delay development of other potential treatments for Alzheimer’s Disease.

To read Patients Rising Now’s full comments, click here.